Pharmaceuticals & Biotech

A three-way deal between Rigel, Arvinas, and Pfizer for vepdegestrant — a protein degrader showing 5.0 months PFS versus 2.1 for fulvestrant in metastatic breast cancer — is setting licensing benchmarks as three FDA decision dates converge between July and October 2026. The cluster is compressing risk timelines for international investors pricing late-stage oncology assets. FDA approvals in this window would trigger parallel EMA and global regulatory filings, accelerating patient access across m

As pharmaceutical companies worldwide compete to unlock the orexin system's therapeutic potential, UK-based Centessa Pharmaceuticals is pursuing one of neuroscience's riskiest frontiers: drugs that activate, rather than block, orexin receptors. The approach promises breakthroughs for millions of narcolepsy sufferers globally, but carries safety unknowns that could prove catastrophic for investors and patients alike.

Tokyo-based Nxera Pharma is drawing scrutiny from international investors for a risk profile familiar across global biotech markets: a pipeline concentrated in just two early-stage clinical assets, where a single failed trial could unravel the entire investment thesis. With one lead candidate yet to reach pivotal trials and another only Phase 2-ready, Nxera exemplifies the binary-risk trap that has claimed valuations from San Francisco to Singapore. The case offers a timely lesson for APAC healt

Swiss biotech Santhera Pharmaceuticals has staked its financial survival on vamorolone, a single drug for Duchenne Muscular Dystrophy approved by the U.S. FDA in 2023. The company's concentrated pipeline reflects a broader tension in global specialty pharma: the pressure to chase rare-disease premiums while exposing investors to catastrophic single-point failure. From Basel to Tokyo, the structural fragility of pipeline-thin biotechs is drawing renewed scrutiny from creditors and regulators alik

Japanese pharmaceutical giant Takeda will discontinue GAMMAGARD S/D by end of 2027, signalling a broader global pivot away from intravenous immunoglobulin formulations toward subcutaneous alternatives. The move reflects strategic portfolio consolidation following Takeda's landmark $62 billion acquisition of Shire, and will reshape competitive dynamics in a plasma-derived therapeutics market worth tens of billions annually. Healthcare systems worldwide will need to manage formulary transitions ah